Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN) will host a conference call on July 29, 2021, at 4:30 p.m. ET to discuss its financial and operating results for Q2 2021, ending June 30, 2021. CEO Panna Sharma will lead the call with management team members. The call can be accessed via toll-free numbers and will be available for replay until August 29, 2021. Lantern Pharma is focused on oncology and utilizes its proprietary RADR® A.I. platform to enhance drug discovery and identify suitable patient profiles for its therapeutics.

Lantern Pharma (LTRN) announced promising preclinical data regarding its drug candidate, LP-184, in collaboration with the Fox Chase Cancer Center. The data showed over 90% tumor shrinkage in pancreatic cancer mouse models within 8 weeks, contrasting with significant tumor growth in untreated mice. The study also indicated that LP-184 is effective against various pancreatic cancer cell lines and patient-derived xenograft models, suggesting its potential for targeted therapy. Additionally, the research validated the role of PTGR1 in enhancing the drug's efficacy, supporting future trials aimed at genetically defined patient populations.

Lantern Pharma Inc. (LTRN) reported its financial results for Q1 2021, highlighting significant advancements in its oncology drug pipeline. The company expanded its RADR® A.I. platform to over 4.6 billion datapoints, nearly a 16-fold increase since its IPO. Lantern's collaboration with Actuate Therapeutics aims to improve insights into the 9-ING-41 drug candidate using RADR® technology. As of March 31, 2021, cash and cash equivalents rose to $81.4 million, while the net loss increased to $2.45 million, consistent with the previous year. The company remains focused on advancing clinical trials and potential partnerships.

Lantern Pharma (NASDAQ: LTRN) announced a research and development collaboration with Actuate Therapeutics to utilize its RADR^® AI platform in the advancement of Actuate's 9-ING-41 drug candidate, a GSK-3β inhibitor undergoing multiple Phase 2 trials. The collaboration aims to enhance drug development through machine learning and oncology datasets, potentially generating joint intellectual property. Lantern expects its RADR^® platform to surpass 10 billion oncology data points within a year, enhancing its capabilities in patient stratification and drug discovery.

Lantern Pharma (LTRN) announced that its RADR® AI platform has surpassed 4.6 billion datapoints, marking a 16-fold increase over the past year. This advancement enhances the platform's drug discovery capabilities across various cancers, focusing on personalized oncology therapeutics. CEO Panna Sharma highlighted the importance of this milestone in speeding up drug development and increasing collaboration opportunities in the biopharma sector. Additionally, Lantern filed two new patents to protect its innovations in AI-driven drug development.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2021, at 4:30 p.m. ET to discuss its first-quarter financial and operating results for the period ending March 31, 2021. The call will feature CEO Panna Sharma and other management members. Lantern Pharma utilizes its proprietary RADR® A.I. platform to advance oncology therapeutics and identify responsive patients. More details on the call can be accessed via the company’s website.

Lantern Pharma Inc. (NASDAQ: LTRN) announced the publication of a manuscript in Oncotarget detailing the efficacy of its drug candidate, LP-184, for treating non-small cell lung cancer (NSCLC). LP-184 has shown nanomolar potency against therapy-resistant NSCLC models, surpassing conventional chemotherapeutics in effectiveness. The unmet need addresses patients resistant to current therapies, with 30-40% of lung cancers lacking targetable mutations. The research identifies patient subgroups likely to respond to LP-184, supporting its potential as a viable treatment option in oncology.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the virtual 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Panna Sharma will engage in a fireside chat on April 15 at 12:45 pm ET and conduct one-on-one investor meetings during the event. The session will be livestreamed and accessible for 90 days on their investor relations website. Lantern Pharma is advancing its proprietary RADR^® A.I. platform for oncology drug development, focusing on genomic-targeted therapeutics.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical firm, announced a collaboration with Johns Hopkins Pediatric Oncology for its drug candidate LP-184, targeting Atypical Teratoid Rhabdoid Tumors (ATRT) in children, an aggressive brain cancer with no effective treatments. The partnership aims to explore LP-184's efficacy across multiple central nervous system cancers, leveraging Lantern's RADR® AI platform. The FDA's Rare Pediatric Disease Designation may enhance LP-184's development, potentially qualifying for a Priority Review Voucher, adding significant value for Lantern's future prospects.